Abstract:The advent of immunotherapy has greatly improved the prognosis of non-small cell lung (NSCLC) patients. However, given its low response rate and high cost of treatment, the search for valuable predictive markers of treatment efficacy is necessary. Considering the complexity and heterogeneity of the tumour and tumour microenvironment, the construction of a multi-dimensional prediction model is necessary. Therefore, we aimed to integrate clinical parameters, radiomic features, and immune signature data from NSCLC patients receiving immunotherapy to construct a multi-dimensional prediction model to better predict the efficacy of immunotherapy. The current study enrolled 137 NSCLC patients who received immunotherapy. We collected baseline clinical information, CT images, and tumour tissue specimens. Using 3D-Slicer software, radiomic features were extracted from patient CT images, and tumor tissue samples obtained before immunotherapy were subjected to immunohistochemical staining. Then, the least absolute shrinkage and selection operator (LASSO) Cox regression analysis was applied to downscale the data, and the radiomic features and immune signatures associated with the prognosis of immunotherapy patients were identified. The modified lung immune predictive index (mLIPI), radiomics score (Radioscore), immune score and multi-dimensional model nomogram were constructed. The C-index and area under the curve (AUC) were applied to evaluate the predictive efficacy of the models. Three radiomic features and three immune signatures that could predict the efficacy of immunotherapy were eventually screened. Multivariate analysis showed that the mLIPI, Radioscore, and immune score were independent predictive factors for PFS and OS ( P < 0.05 for all models). The multi-dimensional model combining the three models showed better predictive efficacy than the mLIPI, Radioscore, and immune score (PFS: 0.721 vs. 0.662 vs. 0.610 vs. 0.610; OS: 0.727 vs. 0.661 vs. 0.601 vs. 0.602 respectively). The multi-dimensional model showed the best predictive efficacy, with C-index for PFS and OS higher than mLIPI, radioscore and immune score: 0.721 vs. 0.662 vs. 0.610 vs. 0.610 for PFS and 0.727 vs. 0.661 vs. 0.601 vs. 0.602 for OS, respectively. The AUC for the multi-dimensional model also performed better than those of the individual models: 0.771 vs. 0.684 vs. 0.715 vs. 0.711 for PFS and 0.768 vs. 0.662 vs. 0.661 vs. 0.658 for OS, respectively. The multi-dimensional model combining the three models had better predictive efficacy than any single model and was more likely to help provide patients personalized and precision medicine.

Three Immunomarker Support Vector Machines-Based Prognostic Classifiers for Stage IB Non-Small-cell Lung Cancer.

Does Selected Immunological Panel Possess the Value of Predicting the Prognosis of Early-Stage Resectable Non-Small Cell Lung Cancer?

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Combined neat model for the prognosis of postoperative stage III-N2 non-small cell lung cancer

Molecular Prognostic Prediction By Support Vector Machine Integrated Approach For Local Advanced Nasopharyngeal Carcinoma.

Multivariate analysis for prognostic predictors in non-small cell lung cancer]

Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer

A New Method for Predicting Survival in Stage I Non-Small Cell Lung Cancer Patients: Nomogram Based on Macrophage Immunoscore, TNM Stage and Lymphocyte-to-monocyte Ratio.

Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC

Molecular Prognostic Prediction For Locally Advanced Nasopharyngeal Carcinoma By Support Vector Machine Integrated Approach

Prognostic nomogram combining 18F-FDG PET/CT radiomics and clinical data for stage III NSCLC survival prediction

A Nomogram Prognostic Model for Clinical Stage IA NSCLC: Based on SEER Databases

Exploring clinical factors to predict the survival of patients with resectable non-small cell lung cancer with neoadjuvant immunotherapy

Study of prognostic predictors for non-small cell lung cancer

Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma

Prognostic Classifier for Stage Ii Gastric Cancer Based by Support Vector Machine.

Preoperative computed tomography-based tumoral radiomic features prediction for overall survival in resectable non-small cell lung cancer

A Prognostic Score System with Lymph Node Ratio in Stage IIIA-N2 NSCLC Patients after Surgery and Adjuvant Chemotherapy

A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel

Development and validation of a nomogram for predicting survival time and making treatment decisions for clinical stage IA NSCLC based on the SEER database

Clinical Characteristics and Prediction Model of Long-Term Survival of Patients with Stage III Non-Small Cell Lung Cancer